Idarucizumab

Drug Profile

Idarucizumab

Alternative Names: BI-655075; Praxbind

Latest Information Update: 05 Jun 2017

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Antidotes; Coagulants; Fab fragments; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Blood coagulation disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Blood coagulation disorders

Most Recent Events

  • 10 May 2017 Phase-I clinical trials in Coagulation disorders (In volunteers) in China (IV) (NCT03086356)
  • 27 Mar 2017 Boehringer Ingelheim plans a phase I trial in Healthy volunteers in China (NCT03086356)
  • 21 Dec 2016 Boehringer Ingelheim completes a phase III trial in Coagulation disorders in the US, Canada, the EU, Argentina, Australia, Brazil, Colombia, Hong Kong, India, Israel, Japan, Mexico, New Zealand, Russia, Singapore, South Africa, South Korea and Taiwan (NCT02104947)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top